Fadzai Teramayi

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity”.

Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease(2023)10.1016/j.bbadis.2023.166848

N/A

0DataRank · unranked

7 citations

Ada Tadeo, Gary K. Scott, Fadzai Teramayi, John J. Tanner, Birgit Schilling +3 more

Brain transcriptomic, metabolic and mitohormesis properties associated with N-propargylglycine treatment: A prevention strategy against neurodegeneration

Brain Research(2023)10.1016/j.brainres.2023.148733

N/A

0DataRank · unranked

4 citations

Joanna Bons, Madeleine Scott, Gary K. Scott, Ashley Loureiro, Alejandro Lopez‐Ramirez +4 more

Selective removal of 7-ketocholesterol by a novel atherosclerosis therapeutic candidate reverts foam cells to a macrophage-like phenotype

Atherosclerosis(2025)10.1016/j.atherosclerosis.2025.119217

N/A

0DataRank · unranked

8 citations

Darren Dinh, Fadzai Teramayi, Ana Silberg, Noa Petler, Amelia Anderson +4 more